Moshe Alafi Net Worth

The estimated Net Worth of Moshe Alafi is at least $295 Million dollars as of 2 October 2017. Moshe Alafi owns over 258,065 units of Intra-Cellular Therapies Inc stock worth over $295,388,334 and over the last 10 years Moshe sold ITCI stock worth over $99,962.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Moshe Alafi ITCI stock SEC Form 4 insiders trading

Moshe has made over 9 trades of the Intra-Cellular Therapies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Moshe bought 258,065 units of ITCI stock worth $4,000,008 on 2 October 2017.

The largest trade Moshe's ever made was buying 258,065 units of Intra-Cellular Therapies Inc stock on 2 October 2017 worth over $4,000,008. On average, Moshe trades about 47,347 units every 133 days since 2014. As of 2 October 2017 Moshe still owns at least 3,953,270 units of Intra-Cellular Therapies Inc stock.

You can see the complete history of Moshe Alafi stock trades at the bottom of the page.

What's Moshe Alafi's mailing address?

Moshe's mailing address filed with the SEC is 8 Admiral Dr, Emeryville, CA 94608, USA.

Insiders trading at Intra-Cellular Therapies Inc

Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus, and Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.

What does Intra-Cellular Therapies Inc do?

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.

Complete history of Moshe Alafi stock trades at Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc executives and stock owners

Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:

• Sharon Mates,
  Chairman of the Board, President, Chief Executive Officer
• Mark Neumann,
  Executive Vice President, Chief Commercial Officer
• Michael Halstead,
  Executive Vice President, General Counsel and Secretary
• Lawrence Hineline,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
• Robert Davis,
  Senior Vice President and Chief Scientific Officer
• Kimberly Vanover,
  Senior Vice President, Early Stage Clinical Development and Translational Medicines
• Dr. Sharon Mates,
  Co-Founder, Chairman, CEO & Pres
• Mark Neumann,
  EVP & Chief Commercial Officer
• Michael I. Halstead J.D.,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Suresh K. Durgam M.D.,
  Sr. VP & Chief Medical Officer
• Lawrence J. Hineline CPA, CPA,
  Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
• Robert Van Nostrand,
  Lead Independent Director
• Joel Marcus,
  Independent Director
• Christopher Alafi,
  Independent Director
• Rory Riggs,
  Independent Director
• Richard Lerner,
  Independent Director
• Michael Olchaskey,
  Senior Vice President, Head of Regulatory Affairs
• Suresh Durgam,
  Chief Medical Officer
• John Bardi,
  Senior Vice President - Market Access, Policy and Government Affairs
• Karen Patruno Sheehy Esq.,
  Sr. VP & Chief Compliance Officer
• Juan Fernando Sanchez,
  VP of Corp. Communications & Investor Relations
• Dr. Robert E. Davis Ph.D.,
  Sr. VP & Chief Scientific Officer
• Moshe Alafi,
  10% owner
• Capital Co Llc Alafi,
  10% owner
• Juan F. Sanchez,
  VP, Corp. Communications & IR
• Allen A. Fienberg,
  VP of Business Development
• Lawrence P. Wennogle,
  Vice President, Drug Discovery
• Michael Rawlins,
  Director
• Eduardo Rene Salas,
  
• Sanjeev Narula,
  Executive Vice President & CFO